Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 04 2025
0mins
Should l Buy TSHA?
Source: SeekingAlpha
Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.
Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.
Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.
Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TSHA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TSHA
Wall Street analysts forecast TSHA stock price to rise
11 Analyst Rating
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.430
Low
8.00
Averages
11.60
High
19.00
Current: 6.430
Low
8.00
Averages
11.60
High
19.00
About TSHA
Taysha Gene Therapies Inc is a clinical-stage biotechnology company, which is focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. The Company’s lead clinical program, TSHA-102, is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder. The Company is evaluating TSHA-102 in the REVEALPhase I/II adolescent and adult clinical trial, which is a first-in-human, open-label, randomized, dose escalation and dose-expansion, multicenter study evaluating the safety and preliminary efficacy of TSHA-102 in female patients aged 12-years and older with Rett syndrome. It has acquired a worldwide right to a clinical-stage, intrathecally dosed AAV9 gene therapy program, TSHA-120, for the treatment of giant axonal neuropathy (GAN). TSHA-105 is a gene replacement therapy in development for the treatment of SLC13A5 deficiency, a rare autosomal recessive epileptic encephalopathy.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Taysha Gene Therapies Reports Better-Than-Expected Earnings
- Earnings Highlights: Taysha Gene Therapies reported a FY GAAP EPS of -$0.34, beating expectations by $0.02, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Revenue Growth: The company reported revenue of $9.77M, a 17.3% year-over-year increase, exceeding market expectations by $3.47M, suggesting sustained demand for its products and potentially laying the groundwork for future profitability.
- Market Reaction: Following the earnings release, investor confidence in the company's prospects has strengthened, likely driving stock price increases, reflecting market recognition of its gene therapy products and optimistic expectations for potential market opportunities.
- Strategic Implications: The positive performance in this earnings report may provide Taysha Gene Therapies with the necessary funding to further invest in and develop its gene therapies, helping it secure a more advantageous position in a competitive market.
See More
Taysha Gene Therapies to Announce FY Earnings Results
- Earnings Announcement Date: Taysha Gene Therapies is set to release its FY earnings report on March 19 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.34, reflecting a 5.6% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still in a loss position.
- Revenue Decline Forecast: Revenue is projected at $6.3 million, representing a 24.4% year-over-year decline, highlighting challenges in market competition and product promotion that may affect investor confidence.
- Performance Beat Record: Over the past year, Taysha has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating a degree of financial management capability despite current challenges.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
Taysha Grants 212,000 Stock Options to New Employees
- Employee Incentive Program: On December 3, 2025, Taysha Gene Therapies granted 212,000 stock options to two new employees at an exercise price of $4.49 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the gene therapy sector.
- Option Structure: These options will be valid for 10 years and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent 36 months, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in talent acquisition, which can bolster investor confidence.
- Strategic Goals: Taysha focuses on developing gene therapies for severe monogenic diseases, particularly its clinical program TSHA-102 for Rett syndrome, and aims to accelerate research and development through these incentive measures to address unmet medical needs.
See More
Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment
Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.
Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.
Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.
Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.
See More
Taysha Gene Therapies Reports Better-Than-Expected Earnings
- Earnings Highlights: Taysha Gene Therapies reported a FY GAAP EPS of -$0.34, beating expectations by $0.02, indicating improvements in cost control and operational efficiency, although the company remains in a loss position.
- Revenue Growth: The company reported revenue of $9.77M, a 17.3% year-over-year increase, exceeding market expectations by $3.47M, suggesting sustained demand for its products and potentially laying the groundwork for future profitability.
- Market Reaction: Following the earnings release, investor confidence in the company's prospects has strengthened, likely driving stock price increases, reflecting market recognition of its gene therapy products and optimistic expectations for potential market opportunities.
- Strategic Implications: The positive performance in this earnings report may provide Taysha Gene Therapies with the necessary funding to further invest in and develop its gene therapies, helping it secure a more advantageous position in a competitive market.
See More
Taysha Gene Therapies to Announce FY Earnings Results
- Earnings Announcement Date: Taysha Gene Therapies is set to release its FY earnings report on March 19 before market open, with investors keenly awaiting performance insights to gauge future growth potential.
- EPS Expectations: The consensus EPS estimate stands at -$0.34, reflecting a 5.6% year-over-year improvement, indicating the company's efforts to enhance profitability, albeit still in a loss position.
- Revenue Decline Forecast: Revenue is projected at $6.3 million, representing a 24.4% year-over-year decline, highlighting challenges in market competition and product promotion that may affect investor confidence.
- Performance Beat Record: Over the past year, Taysha has beaten EPS estimates 50% of the time and revenue estimates 75% of the time, demonstrating a degree of financial management capability despite current challenges.
See More
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
- FDA Drug Rejections: The U.S. FDA has denied or discouraged applications for at least eight drugs over the past year, including UniQure's gene therapy for Huntington's disease, indicating regulatory uncertainty that could impact future treatment approvals.
- Investor Concerns Rise: Investors are increasingly wary as the FDA appears to change its standards for drug applications, particularly for treatments targeting hard-to-treat diseases, leading to diminished confidence in ongoing development efforts.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled trials contradicts previous guidance, highlighting inconsistencies in the agency's approval process that may create uncertainty for companies in their R&D efforts.
- Uncertain Future Outlook: Analysts warn that if the FDA does not approve Denali Therapeutics' drug for Hunter syndrome, it could further undermine other companies' confidence in running open-label studies, potentially stifling innovation across the industry.
See More
FDA Drug Approval Uncertainty Intensifies
- Drug Applications Denied: According to RTW Investments, the FDA has denied or discouraged applications for at least eight new drugs over the past year, including gene therapies for Huntington's and Hunter syndrome, raising investor concerns about the prospects for other drugs in the pipeline.
- Changing Regulatory Standards: The FDA's request for UniQure to conduct new placebo-controlled studies contradicts previous guidance, leading investors to doubt the agency's consistency and fearing that this could jeopardize future treatment approvals.
- Negative Market Reaction: Stocks of several biotech companies have declined following FDA rejections, with analysts noting a stark conflict between the FDA's recent decisions and the flexibility promised by its leadership, causing investors to lose confidence in companies relying on FDA leniency.
- Uncertain Future Outlook: Although FDA officials assert that biomarkers can lead to accelerated approvals, investors remain confused about the agency's approval standards, particularly for drugs targeting rare diseases, making future approval pathways increasingly uncertain.
See More
Taysha Grants 212,000 Stock Options to New Employees
- Employee Incentive Program: On December 3, 2025, Taysha Gene Therapies granted 212,000 stock options to two new employees at an exercise price of $4.49 per share, aimed at attracting and retaining key talent, thereby enhancing the company's competitive edge in the gene therapy sector.
- Option Structure: These options will be valid for 10 years and vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting in equal monthly installments over the subsequent 36 months, ensuring continued employee contributions during their tenure.
- Compliance Assurance: The stock option grant complies with Nasdaq Listing Rule 5635(c)(4), demonstrating the company's commitment to transparency and compliance in talent acquisition, which can bolster investor confidence.
- Strategic Goals: Taysha focuses on developing gene therapies for severe monogenic diseases, particularly its clinical program TSHA-102 for Rett syndrome, and aims to accelerate research and development through these incentive measures to address unmet medical needs.
See More
Goldman Sachs Upgrades Taysha Gene Therapies Due to Progress in Rett Syndrome Treatment
Goldman Sachs Upgrade: Goldman Sachs has upgraded Taysha Gene Therapies (TSHA) to a buy rating, citing progress with its Rett syndrome candidate TSHA-102, which has moved into phase 3 trials.
Price Target and Market Potential: The investment bank set a price target of $11, indicating a potential upside of approximately 145%, and estimates global peak sales for TSHA-102 could reach $3 billion.
Positive Analyst Outlook: Analyst Salveen Richter expressed optimism about the late-stage trial results, noting that TSHA-102 is differentiated from competitor Neurogene's gene therapy based on clinical and safety data.
Recent Stock Performance: Taysha's stock has seen an increase of about 11% in trading, reflecting positive market sentiment following the upgrade and developments in their clinical trials.
See More
